Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 22
Filtrar
1.
Thorac Res Pract ; 24(2): 85-90, 2023 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-37503644

RESUMO

OBJECTIVE: Mannose-binding lectin deficiency may predispose children to having increased infection susceptibility. However, there is no conclusive evidence that mannose-binding lectin deficiency is associated with adverse respiratory consequences in children. We aimed to evaluate the effects of mannose-binding lectin deficiency (defined as a level of less than 0.6 mg/L) on clinical, radiological, and microbiological characteristics in children presenting with troublesome respiratory symptoms, as compared to those who are mannosebinding lectin-sufficient. MATERIAL AND METHODS: We conducted a retrospective cohort study to investigate the association between mannose-binding lectin deficiency and respiratory outcomes in children over a period of 10 years in a large teaching hospital. Children presenting with frequent or persistent respiratory symptoms such as a chronic wet cough lasting more than 4 weeks, recurrent lower respiratory tract infections (≥4 infections in a year), or severe respiratory tract infections requiring admission to intensive care or to high dependency unit were included in the study. RESULTS: The study showed no significant difference in clinical outcomes with mannose-binding lectin deficiency and sufficiency. Thirty-two percent of children with mannose-binding lectin deficiency and 30% of those with mannose-binding lectin sufficiency had positive respiratory microbiology. Twenty-three percent of children with mannose-binding lectin deficiency and 24% of those with mannose-binding lectin sufficiency had radiological changes on plain radiographs; also the prevalence of bronchiectasis was similar in both groups. The rates of admission to pediatric intensive care unit were comparable in the 2 groups. CONCLUSIONS: Children with mannose-binding lectin deficiency and sufficiency showed similar clinical, radiological, and microbiological characteristics. Our study suggests that there are no childhood adverse respiratory consequences with mannose-binding lectin deficiency.

2.
Cancer Med ; 12(13): 14663-14673, 2023 07.
Artigo em Inglês | MEDLINE | ID: mdl-37264737

RESUMO

BACKGROUND/OBJECTIVES: Ataxia telangiectasia (A-T) is a multiorgan disorder with increased vulnerability to cancer. Despite this increased cancer risk, there are no widely accepted guidelines for cancer surveillance in people affected by A-T. We aimed to understand the current international practice regarding cancer surveillance in A-T and agreed-upon approaches to develop cancer surveillance in A-T. DESIGN/METHODS: We used a consensus development method, the e-Delphi technique, comprising three rounds. Round 1 consisted of a Delphi questionnaire and a survey that collected the details of respondents' professional background, experience, and current practice of cancer surveillance in A-T. Rounds 2 and 3 were designed based on previous rounds and modified according to the comments made by the panellists. The pre-specified consensus threshold was ≥75% agreement. RESULTS: Thirty-five expert panellists from 13 countries completed the study. The survey indicated that the current practice of cancer surveillance varies widely between experts and centres'. Consensus was reached that evidence-based guidelines are needed for cancer surveillance in people with A-T, with separate recommendations for adults and children. Statements relating to the tests that should be included, the age for starting and stopping cancer surveillance and the optimal surveillance interval were also agreed upon, although in some areas, the consensus was that further research is needed. CONCLUSION: The international expert consensus statement confirms the need for evidence-based cancer surveillance guidelines in A-T, highlights key features that the guidelines should include, and identifies areas of uncertainty in the expert community. This elucidates current knowledge gaps and will inform the design of future clinical trials.


Assuntos
Ataxia Telangiectasia , Neoplasias , Adulto , Criança , Humanos , Ataxia Telangiectasia/complicações , Ataxia Telangiectasia/diagnóstico , Consenso , Técnica Delphi , Inquéritos e Questionários
3.
Crit Care Med ; 50(2): e173-e182, 2022 02 01.
Artigo em Inglês | MEDLINE | ID: mdl-34524154

RESUMO

OBJECTIVES: Electronic cigarette or vaping product use-associated lung injury is a clinical entity that can lead to respiratory failure and death. Despite the severity of electronic cigarette or vaping product use-associated lung injury, the role of extracorporeal life support in its management remains unclear. Our objective was to describe the clinical characteristics and outcomes of patients with electronic cigarette or vaping product use-associated lung injury who received extracorporeal life support. DESIGN: We performed a retrospective review of records of electronic cigarette or vaping product use-associated lung injury patients who received extracorporeal life support. Standardized data were collected via direct contact with extracorporeal life support centers. Data regarding presentation, ventilatory management, extracorporeal life support details, and outcome were analyzed. SETTING: This was a multi-institutional, international case series with patients from 10 different institutions in three different countries. PATIENTS: Patients who met criteria for confirmed electronic cigarette or vaping product use-associated lung injury (based on previously reported diagnostic criteria) and were placed on extracorporeal life support were included. Patients were identified via literature review and by direct contact with extracorporeal life support centers. MEASUREMENTS AND MAIN RESULTS: Data were collected for 14 patients ranging from 16 to 45 years old. All had confirmed vape use within 3 months of presentation. Nicotine was the most commonly used vaping product. All patients had respiratory symptoms and radiographic evidence of bilateral pulmonary opacities. IV antibiotics and corticosteroids were universally initiated. Patients were intubated for 1.9 days (range, 0-6) prior to extracorporeal life support initiation. Poor oxygenation and ventilation were the most common indications for extracorporeal life support. Five patients showed evidence of ventricular dysfunction on echocardiography. Thirteen patients (93%) were placed on venovenous extracorporeal life support, and one patient required multiple rounds of extracorporeal life support. Total extracorporeal life support duration ranged from 2 to 37 days. Thirteen patients survived to hospital discharge; one patient died of septic shock. CONCLUSIONS: Electronic cigarette or vaping product use-associated lung injury can cause refractory respiratory failure and hypoxemia. These data suggest that venovenous extracorporeal life support can be an effective treatment option for profound, refractory respiratory failure secondary to electronic cigarette or vaping product use-associated lung injury.


Assuntos
Sistemas Eletrônicos de Liberação de Nicotina/estatística & dados numéricos , Oxigenação por Membrana Extracorpórea/estatística & dados numéricos , Lesão Pulmonar/etiologia , Insuficiência Respiratória/etiologia , Vaping/efeitos adversos , Adolescente , Adulto , Oxigenação por Membrana Extracorpórea/métodos , Feminino , Humanos , Pulmão/anormalidades , Pulmão/fisiopatologia , Lesão Pulmonar/complicações , Lesão Pulmonar/epidemiologia , Masculino , Pessoa de Meia-Idade , Insuficiência Respiratória/epidemiologia , Estudos Retrospectivos , Vaping/epidemiologia
4.
Paediatr Respir Rev ; 39: 82-89, 2021 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-33309219

RESUMO

Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease commonly seen in preterm infants as the sequelae following respiratory distress syndrome. The management of evolving BPD aims to minimise lung injury and prevent the impact of hypoxia and hyperoxia. Proposed morbidities include respiratory instability, pulmonary hypertension, suboptimal growth, altered cerebral oxygenation and long-term neurodevelopmental impairment. The ongoing management and associated morbidity present a significant burden for carers and healthcare systems. Long-term oxygen therapy may be required for variable duration, though there is a lack of consensus and wide variation in practise when weaning supplemental oxygen. Furthermore, a shift in care towards earlier discharge and community care underlines the importance of a structured discharge and weaning process that eliminates the potential risks associated with hypoxia and hyperoxia. This review article describes recent evidence outlining oxygen saturation reference ranges in young infants, on which structured guidance can be based.


Assuntos
Displasia Broncopulmonar , Displasia Broncopulmonar/terapia , Humanos , Lactente , Recém-Nascido , Recém-Nascido Prematuro , Oxigênio , Oxigenoterapia , Desmame
5.
Breathe (Sheff) ; 16(2): 200003, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-32684994

RESUMO

Paediatric pulmonary Langerhans cell histiocytosis (pPLCH) is a rare diffuse cystic lung disease. Unlike pulmonary Langerhans cell histiocytosis (LCH) in adults, which is often seen as an isolated condition with smoking being a major risk factor, isolated pPLCH is vanishingly rare in children and it is most often a component of multisystem LCH. Diagnosis should be based on histological and immunophenotypic examination of affected tissue in addition to clinical and radiological features. It should be considered an important differential for diffuse cystic lung disease in paediatric patients. Recent progress in the biological understanding of the disease supports the classification of LCH as an inflammatory myeloid neoplasia. Chemotherapy and specific management of respiratory complications are the mainstays of treatment. The lungs are no longer considered a "risk organ" in LCH as pulmonary involvement is not associated with a worse prognosis than the involvement of other organs. Multidisciplinary treatment approaches are needed. Prognosis can be good but is adversely influenced by multisystem involvement, and complications such as pneumothoraces and respiratory failure can be life threatening. This review aims to give an overview of this condition, with a focus on the diagnosis, monitoring and management of complications such as pneumothoraces and respiratory failure, which can be challenging for the paediatric respiratory specialist. EDUCATIONAL AIMS: To give an overview of paediatric pulmonary LCH.To discuss the differential diagnosis of paediatric cystic lung disease.

6.
Pediatr Pulmonol ; 55(8): 2074-2081, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32511892

RESUMO

Patients with pulmonary Langerhans cell histiocytosis (LCH) typically have a benign course but may have extensive cystic lung disease with rare life-threatening complications including multiple and recurrent pneumothoraces and respiratory failure. We report seven severely affected pediatric patients treated with chemotherapy, aggressive chest tube management, and pleurodesis of whom five survived. Patients with extraordinary amounts of pulmonary cystic disease and multiple pneumothoraces due to LCH can have remarkable, curative outcomes with early recognition, optimal LCH-directed therapy, and supportive care.


Assuntos
Histiocitose/terapia , Pneumopatias/terapia , Pneumotórax/terapia , Adolescente , Tubos Torácicos , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Pleurodese
8.
Eur Respir J ; 54(3)2019 09.
Artigo em Inglês | MEDLINE | ID: mdl-31320455

RESUMO

Tracheomalacia and tracheobronchomalacia may be primary abnormalities of the large airways or associated with a wide variety of congenital and acquired conditions. The evidence on diagnosis, classification and management is scant. There is no universally accepted classification of severity. Clinical presentation includes early-onset stridor or fixed wheeze, recurrent infections, brassy cough and even near-death attacks, depending on the site and severity of the lesion. Diagnosis is usually made by flexible bronchoscopy in a free-breathing child but may also be shown by other dynamic imaging techniques such as low-contrast volume bronchography, computed tomography or magnetic resonance imaging. Lung function testing can provide supportive evidence but is not diagnostic. Management may be medical or surgical, depending on the nature and severity of the lesions, but the evidence base for any therapy is limited. While medical options that include bronchodilators, anti-muscarinic agents, mucolytics and antibiotics (as well as treatment of comorbidities and associated conditions) are used, there is currently little evidence for benefit. Chest physiotherapy is commonly prescribed, but the evidence base is poor. When symptoms are severe, surgical options include aortopexy or posterior tracheopexy, tracheal resection of short affected segments, internal stents and external airway splinting. If respiratory support is needed, continuous positive airway pressure is the most commonly used modality either via a face mask or tracheostomy. Parents of children with tracheobronchomalacia report diagnostic delays and anxieties about how to manage their child's condition, and want more information. There is a need for more research to establish an evidence base for malacia. This European Respiratory Society statement provides a review of the current literature to inform future study.


Assuntos
Broncomalácia/diagnóstico por imagem , Broncomalácia/terapia , Pneumologia/normas , Traqueomalácia/diagnóstico por imagem , Traqueomalácia/terapia , Broncoscopia , Criança , Europa (Continente) , Humanos , Imageamento por Ressonância Magnética , Tomografia Computadorizada Multidetectores , Modalidades de Fisioterapia , Pneumologia/organização & administração , Testes de Função Respiratória , Sons Respiratórios , Sociedades Médicas
9.
Breathe (Sheff) ; 14(1): 5-7, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-29515661

RESUMO

Introducing a new series of articles focusing on myths and maxims related to conditions clinicians in paediatric respiratory medicine encounter on a regular basis http://ow.ly/sUid30hWIs2.

10.
Arch Dis Child ; 102(4): 328-330, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-27799156

RESUMO

BACKGROUND AND AIMS: Ataxia telangiectasia (A-T) is a rare progressive, multisystem genetic disease. Families of children with ultra-rare diseases often experience significant diagnostic delays. We reviewed the diagnostic process for A-T in order to identify causes of delay in an attempt to facilitate earlier identification of A-T in the future. METHODS: A retrospective case note review of 79 children at the National Paediatric A-T clinic seen since May 2009. Data were collected on the nature and age of initial symptoms, the age at first presentation, measurement of alpha feto-protein (AFP) and age of genetic diagnostic confirmation. RESULTS: At presentation, 71 children (90%) had ataxia. The median presentation delay (from first parental concern to presentation) was 8 months (range 0-118 months), and the median diagnostic delay (genetic confirmation of diagnosis) was 12 months (range 1-109 months). CONCLUSIONS: There are significant delays in presentation and diagnostic confirmation of A-T. A greater awareness of A-T and early measurement of AFP may help to improve this.


Assuntos
Ataxia Telangiectasia/diagnóstico , Fatores Etários , Criança , Pré-Escolar , Diagnóstico Tardio , Humanos , Lactente , Estudos Retrospectivos , alfa-Fetoproteínas/metabolismo
11.
Arch Dis Child ; 101(12): 1137-1141, 2016 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-27573920

RESUMO

BACKGROUND: Ataxia telangiectasia (A-T) is a rare multisystem disease with high early mortality from lung disease and cancer. Nutritional failure adversely impacts outcomes in many respiratory diseases. Several factors influence nutrition in children with A-T. We hypothesised that children with A-T have progressive growth failure and that early gastrostomy tube feeding (percutaneous endoscopic gastrostomy, PEG) is a favourable management option with good nutritional outcomes. METHODS: Data were collected prospectively on weight, height and body mass index (BMI) at the national paediatric A-T clinic. Adequacy and safety of oral intake was assessed. Nutritional advice was given at each multidisciplinary review. RESULTS: 101 children (51 girls) had 222 measurements (32 once, 32 twice, 24 thrice) between 2009 and 2016. Median (IQR) age was 9.3 (6.4 to 13.1) years. Mean (SD) weight, height and BMI Z-scores were respectively -1 (1.6), -1.2 (1.2) and -0.4 (1.4). 35/101 children had weight Z-scores below -2 on at least one occasion. Weight, height and BMI Z-scores declined over time. Decline was most obvious after 8 years of age. 14/101 (14%) children had a PEG, with longitudinal data available for 12. In a nested case control study, there was a trend for improvement in weight in those with a PEG (p=0.10). CONCLUSIONS: Patients with A-T decline in growth over time. There is an urgent need for new strategies, including an understanding of why growth falters. We suggest early proactive consideration of PEG from age 8 years onwards to prevent progressive growth failure.


Assuntos
Ataxia Telangiectasia/complicações , Transtornos do Crescimento/etiologia , Estatura/fisiologia , Índice de Massa Corporal , Peso Corporal/fisiologia , Estudos de Casos e Controles , Criança , Nutrição Enteral/estatística & dados numéricos , Feminino , Transtornos do Crescimento/dietoterapia , Humanos , Masculino , Estado Nutricional/fisiologia , Estudos Prospectivos , Resultado do Tratamento
12.
Br J Hosp Med (Lond) ; 77(4): 212-5, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-27071426

RESUMO

Bronchiolitis is common in infants. Oxygen therapy, fluids and occasionally respiratory support remain the mainstay of treatment. The NICE guidelines are expected to streamline the management of bronchiolitis and minimize potentially harmful interventions. Further research to find other useful therapies is necessary.


Assuntos
Bronquiolite/terapia , Guias de Prática Clínica como Assunto , Bronquiolite/epidemiologia , Medicina Baseada em Evidências , Humanos , Lactente , Recém-Nascido , Medicina Estatal , Reino Unido/epidemiologia
13.
Adv Neonatal Care ; 16(1): 17-25;quiz E1-2, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26734814

RESUMO

BACKGROUND: Bronchopulmonary dysplasia (BPD), also known as chronic lung disease of prematurity or chronic neonatal lung disease, is a major cause of respiratory illness in premature babies. Newborn babies survive at gestational ages of 23 to 26 weeks, earlier than when BPD was first described. New mechanisms of lung injury have therefore emerged and the clinical and pathological characteristics of pulmonary involvement have changed. PURPOSE: Improved neonatal intensive care unit modalities have increased survival rates; the overall prevalence of the condition, however, has not changed. Management of evolving BPD aims at minimizing lung injury. Management of established, especially severe BPD, still poses significant clinical challenge as these babies need long-term oxygen therapy (LTOT) for variable length of time. We aim to give an overview of management of established BPD with particular focus on weaning home oxygen therapy at our local center in the United Kingdom. SEARCH AND RESULTS: On the basis of most recent evidence, we concluded that an integrated pathway for managing babies on LTOT is very important after discharge from neonatal unit. IMPLICATIONS FOR PRACTICE: A structured weaning pathway for premature babies on home oxygen improves outcome. IMPLICATIONS FOR RESEARCH: The management of severe BPD and related complications, particularly during the first 2 years of life, remains a continuing challenge for parents and healthcare providers. The most beneficial respiratory support strategy to minimize lung injury and/or promote lung healing remains unclear and requires further investigation.


Assuntos
Displasia Broncopulmonar/etiologia , Displasia Broncopulmonar/enfermagem , Lesão Pulmonar/etiologia , Lesão Pulmonar/enfermagem , Enfermagem Neonatal/educação , Oxigenoterapia/efeitos adversos , Síndrome do Desconforto Respiratório do Recém-Nascido/enfermagem , Pré-Escolar , Educação Continuada em Enfermagem , Feminino , Humanos , Lactente , Recém-Nascido , Recém-Nascido Prematuro , Terapia Intensiva Neonatal/métodos , Masculino , Enfermagem Neonatal/métodos , Recursos Humanos de Enfermagem Hospitalar/educação
15.
Eur Respir Rev ; 24(138): 565-81, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26621971

RESUMO

Ataxia telangiectasia (A-T) is a rare, progressive, multisystem disease that has a large number of complex and diverse manifestations which vary with age. Patients with A-T die prematurely with the leading causes of death being respiratory diseases and cancer. Respiratory manifestations include immune dysfunction leading to recurrent upper and lower respiratory infections; aspiration resulting from dysfunctional swallowing due to neurodegenerative deficits; inefficient cough; and interstitial lung disease/pulmonary fibrosis. Malnutrition is a significant comorbidity. The increased radiosensitivity and increased risk of cancer should be borne in mind when requesting radiological investigations. Aggressive proactive monitoring and treatment of these various aspects of lung disease under multidisciplinary expertise in the experience of national multidisciplinary clinics internationally forms the basis of this statement on the management of lung disease in A-T. Neurological management is outwith the scope of this document.


Assuntos
Ataxia Telangiectasia/terapia , Pneumopatias/terapia , Pulmão , Equipe de Assistência ao Paciente/normas , Pneumologia/normas , Ataxia Telangiectasia/diagnóstico , Ataxia Telangiectasia/genética , Ataxia Telangiectasia/imunologia , Ataxia Telangiectasia/mortalidade , Ataxia Telangiectasia/fisiopatologia , Terapia Combinada , Comorbidade , Comportamento Cooperativo , Predisposição Genética para Doença , Humanos , Comunicação Interdisciplinar , Pulmão/imunologia , Pulmão/patologia , Pulmão/fisiopatologia , Pneumopatias/diagnóstico , Pneumopatias/genética , Pneumopatias/imunologia , Pneumopatias/mortalidade , Pneumopatias/fisiopatologia , Valor Preditivo dos Testes , Fatores de Risco , Espirometria/normas , Tomografia Computadorizada por Raios X/normas , Resultado do Tratamento
16.
Br J Hosp Med (Lond) ; 76(7): 398-404, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-26140558

RESUMO

Chronic moist cough in children can be associated with serious pathologies. Protracted bacterial bronchitis remains a clinical diagnosis causing persistent moist cough, disturbed sleep, exercise intolerance and significant levels of morbidity. Management involves minimal investigations and prolonged courses of antibiotics.


Assuntos
Antibacterianos/uso terapêutico , Infecções Bacterianas/diagnóstico , Infecções Bacterianas/tratamento farmacológico , Bronquite/diagnóstico , Bronquite/tratamento farmacológico , Infecções Bacterianas/fisiopatologia , Bronquite/fisiopatologia , Líquido da Lavagem Broncoalveolar/microbiologia , Broncoscopia , Criança , Doença Crônica , Tosse , Diagnóstico Diferencial , Humanos
18.
Indian J Pediatr ; 81(11): 1193-5, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24920441

RESUMO

Recurrent wheezing is common in preschool children and often gets labelled as asthma. It is important to differentiate preschool wheeze from asthma through focused history, examination and exclusion of other serious conditions that may present as wheeze. Two different pragmatic clinical phenotypes viz. episodic viral wheeze (EVW) and multi-trigger wheeze (MTW) have been described although categories do not remain fixed and cross over is often seen in clinical practice. Episodic use of inhaled bronchodilators such as salbutamol when wheezy, is the mainstay of treatment along with non-pharmacological measures such as avoidance of environmental tobacco smoke and parental education. Inhaled corticosteroids are the first choice for maintenance therapy in MTW whereas montelukast may be useful when maintenance therapy is considered in EVW. Any maintenance therapy should be viewed as a trial and need to be discontinued in cases where no benefit has been demonstrated. Short term systemic steroid therapy should be reserved for excaerbation of wheezy symptoms where hospitalization is necessary. Prognosis is good in recurrent mild EVW although remission in atopic MTW is often not achieved and the children in the latter group go on to develop asthma.


Assuntos
Asma/diagnóstico , Sons Respiratórios/diagnóstico , Corticosteroides/uso terapêutico , Antiasmáticos/uso terapêutico , Asma/tratamento farmacológico , Broncodilatadores/uso terapêutico , Pré-Escolar , Diagnóstico Diferencial , Humanos , Fenótipo , Prognóstico , Sons Respiratórios/efeitos dos fármacos , Fatores de Risco
20.
Eur Respir Rev ; 22(129): 205-16, 2013 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-23997047

RESUMO

Pulmonary exacerbations have very important consequences in cystic fibrosis (CF), both in terms of current morbidity as well as implications for long term morbidity and mortality. Even though there is no universally agreed definition of pulmonary exacerbation, prompt and aggressive treatment with a multidisciplinary approach is recommended. Maintenance treatments reduce the risk of exacerbations. Antibiotics should be targeted against the common CF bacteria and these can be given orally, although i.v. antibiotics will be required for ongoing symptoms or severe exacerbations. The evidence base for recommendations regarding the optimal regimens, route and frequency of administration of antibiotics, location, and duration of i.v. antibiotic treatment will be discussed. Management of comorbidities, like poor nutrition and diabetes, is critical in improving outcomes.


Assuntos
Antibacterianos/administração & dosagem , Fibrose Cística/tratamento farmacológico , Infecções Respiratórias/tratamento farmacológico , Comorbidade , Fibrose Cística/diagnóstico , Fibrose Cística/epidemiologia , Progressão da Doença , Vias de Administração de Medicamentos , Esquema de Medicação , Humanos , Equipe de Assistência ao Paciente , Guias de Prática Clínica como Assunto , Infecções Respiratórias/diagnóstico , Infecções Respiratórias/epidemiologia , Fatores de Risco , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...